Revvity announced that its adjusted profit per share for full year 2025 is now expected to exceed the previously guided range of $4.90 to $5.00. Management cited stronger-than-anticipated demand for contract research and diagnostics services, driven by accelerated spending from pharmaceutical and biotech customers. This upward revision reflects continued margin expansion in its specialty diagnostics unit and operational leverage across lab consumables and workflow solutions. In its pre-release update, Revvity projected fourth quarter revenue of approximately $772 million, reflecting reported growth of 6% and organic growth of 4% versus the year-ago quarter. For the full year 2025, reported revenue is expected at $2,855 million, up 4% year-over-year, with organic growth of 3%. These results incorporate a 1–2% headwind from foreign exchange and no material contribution from acquisitions, underscoring solid underlying demand across its translational multi-omics, biomarker identification and imaging franchises. Revvity entered a collaboration with Eli Lilly to integrate its TuneLab AI drug discovery models into the Signals Xynthetica federated platform. The alliance aims to enable secure, cross-institutional model training without data sharing, potentially reducing candidate discovery timelines by up to 30%. Analysts note that this partnership enhances Revvity’s informatics portfolio and positions the company as a key provider of next-generation AI tools for preclinical research.